530 related articles for article (PubMed ID: 12972522)
21. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
24. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
[TBL] [Abstract][Full Text] [Related]
25. Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed.
Wiedswang G; Borgen E; Karesen R; Naume B
Cytotherapy; 2003; 5(1):40-5. PubMed ID: 12745581
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
27. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
[TBL] [Abstract][Full Text] [Related]
28. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
29. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
[TBL] [Abstract][Full Text] [Related]
32. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
33. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
34. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
[TBL] [Abstract][Full Text] [Related]
35. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
36. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
Wapnir IL; Anderson SJ; Mamounas EP; Geyer CE; Jeong JH; Tan-Chiu E; Fisher B; Wolmark N
J Clin Oncol; 2006 May; 24(13):2028-37. PubMed ID: 16648502
[TBL] [Abstract][Full Text] [Related]
37. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.
Fehm T; Becker S; Pergola-Becker G; Krämer B; Gruber I; Sotlar K; Kurek R; Wallwiener D; Solomayer E
Anticancer Res; 2004; 24(6):4211-6. PubMed ID: 15736474
[TBL] [Abstract][Full Text] [Related]
38. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
39. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
40. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
